US48669G1058 - ADR
KAZIA THERAPEUTICS-SPON ADR
NASDAQ:KZIA (3/28/2024, 8:21:05 PM)
After market: 0.2804 -0.03 (-9.49%)0.3098
0 (-1.24%)
Kazia Therapeutics Ltd is a AU-based company operating in Biotechnology industry. The company is headquartered in Sydney, New South Wales. Kazia Therapeutics Limited is an oncology focused drug development company. The firm is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.
KAZIA THERAPEUTICS-SPON ADR
Three International Towers Level 24,, 300 Barangaroo Avenue
Sydney NEW SOUTH WALES 2000
P: 1161298780088
CEO: James Garner
Employees: 0
Website: https://www.kaziatherapeutics.com/
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that it has entered into an...
Pre-market stock movers are worth checking out as we dive into all of the biggest movements worth reading about on Wednesday morning!
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Kazia (KZIA) said it has concluded a Phase 1 trial for its drug paxalisib in the treatment of a certain type of brain metastases early due to encouraging data. Read more here.
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on...
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma...
Here you can normally see the latest stock twits on KZIA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: